Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $52.5B | $51.3B | $48.4B | $48.4B | $48.3B | $50.0B | $67.8B | $67.4B | $59.0B | $51.6B | $49.6B | $48.9B | $52.8B | $52.5B | $53.6B | $51.8B | $41.9B | $81.3B | $100.3B | $58.5B |
Discover the top 20 best undervalued stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Nov 2024.
As of today, Pfizer Inc.'s last 12-month Revenue is $60.1B, based on the financial report for Sep 29, 2024 (Q3 2024).
Over the last year, Pfizer Inc.'s Revenue growth was (12.3%). The average annual Revenue growth rates for Pfizer Inc. have been 6.2% over the past three years, 2.5% over the past five years.
Over the last year, Pfizer Inc.'s Revenue growth was (12.3%), which is lower than industry growth of 0.1%. It indicates that Pfizer Inc.'s Revenue growth is Bad.